Newport Beach, CANCT07793409Now EnrollingIRB Ready

Chronic Obstructive Pulmonary Disease Clinical Trial in Newport Beach, CA

Access cutting-edge chronic obstructive pulmonary disease treatment through this phase 3 clinical trial at a research site in Newport Beach. Study-provided care at no cost to qualified participants.

Sponsored by Sanofi

Quick Self-Assessment

See if you qualify for this Newport Beach location

Preparing your pre-screening questions…

Expert Care in Newport Beach

Access chronic obstructive pulmonary disease specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related chronic obstructive pulmonary disease treatment provided free

Apply for This Newport Beach Location

Check if you qualify for this chronic obstructive pulmonary disease clinical trial in Newport Beach, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Newport Beach

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Newport Beach site if eligible
  4. 4Begin participation

About This Chronic Obstructive Pulmonary Disease Study in Newport Beach

This is an open-label, Phase 3, long-term safety extension study including participants of previous lunsekimig clinical trials with inadequately controlled chronic obstructive pulmonary disease (COPD ) characterized by an eosinophilic phenotype. The purpose of the LTS 18211 study is to characterize the long-term safety and efficacy of lunsekimig in adults with COPD who completed studies EFC18243 or EFC18244 in the main study, and to assess the impact of inhaled corticosteroids (ICS ) withdrawal in the ICS withdrawal sub-study. The study duration will be up to 100 weeks, including the following components: * Baseline Visit (Visit 1 / Week 0) will coincide with the End-of-Intervention visit from the parent study (EFC18243 or EFC18244) if possible * Treatment duration of up to 96 weeks * Safety follow-up period of approximately 4 weeks * The number of visits will be 26

Sponsor: Sanofi

Who Can Participate

Inclusion Criteria

Participants who completed the treatment period of EFC18243 or EFC18244 studies, including EOI visit
Contraception for male and female participants during the study intervention period and during 8 weeks following the last administration of study intervention. And:
Female participants: not pregnant or breastfeeding, and one of the following conditions applies:
Is not a women of childbearing potential (WOCBP), OR
Is a WOCBP and agrees to follow the contraceptive guidance. The WOCBP should also agree not to donate or cryopreserve eggs (ova, oocytes) for the purpose of reproduction.
Male participants: No sperm donation or cryopreserving sperm ICS-withdrawal sub-study only:
Participants receiving triple controller therapy (LABA+LAMA+ICS)
Participants who were compliant with lunsekimig
≤ 1 moderate exacerbation and no severe exacerbation of COPD during the parent study
No exacerbation during the run-in period

Exclusion Criteria

The exclusion criteria are identical for LTS18211 and ICS withdrawal sub-study:
Participant who developed a new medical condition or a change in status of an established medical condition or requires a new treatment or medication prior to enrollment that, per Investigator's medical judgement, would adversely affect participation of the participant in this study or would require permanent lunsekimig discontinuation, or participant potentially at risk of noncompliance to study procedures
Prescription drug or substance abuse, including alcohol, considered significant by the Investigator
History of hypersensitivity or allergy to lunsekimig or to any of the excipients used in the presentation or in preparation for administration of lunsekimig, or other allergy that, in the opinion of the Investigator, contraindicates participation in the study
Participants who are receiving prohibited concomitant medications at LTS18211 baseline
Participants who, during their participation in the parent study, developed an AE or an SAE deemed related to lunsekimig, and for whom continuation of treatment with lunsekimig may present an unreasonable risk The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Newport Beach?

Yes, this clinical trial (NCT07793409) has an active research site in Newport Beach, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Chronic Obstructive Pulmonary Disease Treatment Options in Newport Beach, CA

If you're searching for chronic obstructive pulmonary disease treatment options in Newport Beach, CA, this clinical trial (NCT07793409) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Newport Beach research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced chronic obstructive pulmonary disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all chronic obstructive pulmonary disease clinical trials near you to find additional studies recruiting in your area.

More Ulcerative Colitis Trials in Newport Beach, CA

See all ulcerative colitis clinical trials recruiting in Newport Beach — not just this study.

Browse Ulcerative Colitis Trials in Newport Beach →

Browse More Trials by Condition

Ulcerative Colitis TrialsAnkylosing Spondylitis TrialsCOPD TrialsInterstitial Cystitis TrialsAll Conditions →

Ready to Join in Newport Beach?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Newport Beach, CA